Literature DB >> 20203556

Respiratory syncytial virus activity - United States, July 2008-December 2009.

.   

Abstract

Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and pneumonia in children aged <1 year worldwide. Each year in the United States, an estimated 75,000-125,000 infants are hospitalized with RSV. Among adults aged >65 years, an estimated 177,000 hospitalizations and 14,000 deaths a year have been attributed to RSV infections. In temperate climates, the RSV season generally begins during the fall and continues through the winter and spring, but the exact timing of RSV circulation varies by location and year. In the United States, data from the National Respiratory and Enteric Virus Surveillance System (NREVSS) are used to monitor the seasonal occurrence of RSV. During the 2008-09 season, onset occurred from mid-October to late December in the 10 U.S. Department of Health and Human Services (HHS) regions, excluding Florida, which had onset in mid-July. Season offset in all regions occurred from mid-February to mid-April. Florida is reported separately because it has an earlier season onset and longer duration than the rest of the country. During the current 2009-10 season, onset occurred in all 10 HHS regions by February 20, 2010. These patterns are similar to previous years and confirm differences in RSV seasonal characteristics across regions. Knowledge of RSV seasonality can be used by clinicians and public health officials to determine when to consider RSV as a cause of acute respiratory illnesses and when to provide RSV immunoprophylaxis to children at high risk for serious disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20203556

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  17 in total

1.  Effect of young sibling visitation on respiratory syncytial virus activity in a NICU.

Authors:  A M Peluso; B A Harnish; N S Miller; E R Cooper; A M Fujii
Journal:  J Perinatol       Date:  2015-04-02       Impact factor: 2.521

Review 2.  Therapeutic targeting of respiratory syncytial virus G-protein.

Authors:  Lawrence M Kauvar; Jennifer L Harcourt; Lia M Haynes; Ralph A Tripp
Journal:  Immunotherapy       Date:  2010-09       Impact factor: 4.196

3.  CpG in Combination with an Inhibitor of Notch Signaling Suppresses Formalin-Inactivated Respiratory Syncytial Virus-Enhanced Airway Hyperresponsiveness and Inflammation by Inhibiting Th17 Memory Responses and Promoting Tissue-Resident Memory Cells in Lungs.

Authors:  Lei Zhang; Hongyong Li; Yan Hai; Wei Yin; Wenjian Li; Boyang Zheng; Xiaomin Du; Na Li; Zhengzheng Zhang; Yuqing Deng; Ruihong Zeng; Lin Wei
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

4.  High-Flow Nasal Cannula versus Continuous Positive Airway Pressure in Critical Bronchiolitis: A Randomized Controlled Pilot.

Authors:  Regina Grigolli Cesar; Bibiane Ramos Pinheiro Bispo; Priscilla Helena Costa Alves Felix; Maria Carolina Caparica Modolo; Andreia Aparecida Freitas Souza; Nelson K Horigoshi; Alexandre T Rotta
Journal:  J Pediatr Intensive Care       Date:  2020-04-17

5.  Phosphatidylglycerol provides short-term prophylaxis against respiratory syncytial virus infection.

Authors:  Mari Numata; Yoji Nagashima; Martin L Moore; Karin Z Berry; Mallory Chan; Pitchaimani Kandasamy; R Stokes Peebles; Robert C Murphy; Dennis R Voelker
Journal:  J Lipid Res       Date:  2013-06-06       Impact factor: 5.922

6.  Effects of human respiratory syncytial virus, metapneumovirus, parainfluenza virus 3 and influenza virus on CD4+ T cell activation by dendritic cells.

Authors:  Cyril Le Nouën; Philippa Hillyer; Shirin Munir; Christine C Winter; Thomas McCarty; Alexander Bukreyev; Peter L Collins; Ronald L Rabin; Ursula J Buchholz
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

7.  Antiviral activity of diarylheptanoid stereoisomers against respiratory syncytial virus in vitro and in vivo.

Authors:  Katsuhiko Konno; Motofumi Miura; Masaharu Toriyama; Shigeyasu Motohashi; Rie Sawamura; Wataru Watanabe; Hiroki Yoshida; Masahiko Kato; Ryuichi Yamamoto; Ken Yasukawa; Masahiko Kurokawa
Journal:  J Nat Med       Date:  2013-01-24       Impact factor: 2.343

8.  A model of the costs of community and nosocomial pediatric respiratory syncytial virus infections in Canadian hospitals.

Authors:  Philip Jacobs; Douglas Lier; Katherine Gooch; Katharina Buesch; Michelle Lorimer; Ian Mitchell
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

9.  Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics.

Authors:  Cindy Luongo; Christine C Winter; Peter L Collins; Ursula J Buchholz
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

10.  Cytokine responses in primary and secondary respiratory syncytial virus infections.

Authors:  Kelechi Ugonna; Konstantinos Douros; Colin D Bingle; Mark L Everard
Journal:  Pediatr Res       Date:  2016-02-16       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.